期刊文献+

124例三阴性乳腺癌临床病理因素与预后分析 被引量:4

Retrospective analysis of clinic-pathological prognostic factors of 124 triple-negative breast cancer patients
下载PDF
导出
摘要 目的:三阴性乳腺癌(triple-negative breast cancer,TNBC)预后差,易复发转移,缺乏有效的治疗手段。本文回顾性分析TNBC及基底细胞型的临床病理因素与预后的关系。方法:纳入江苏省肿瘤医院124例TNBC,Fisher法分析临床病理因素之间的相关性,Kaplan-Meier法分析Ki-67/p53与无进展生存期的相关性,COX回归模型分析无进展生存期的预后因素。结果:TNBC肿块大小与腋窝淋巴结转移相关,Ki-67高表达与腋窝淋巴结转移相关,p53阳性与病理分级相关。TNBC及基底细胞型中,Ki-67高增殖与p53阳性患者具有相对较差的无病生存期(P<0.05)。临床分期、腋窝淋巴结转移阳性、Ki-67高增殖与p53阳性是TNBC无病生存的独立预后因素。结论:本文证实Ki-67及p53是TNBC生存预后的预测因子,为TNBC延长生存、改善预后提供依据。 Objective: Triple-negative breast cancer(TNBC) is an aggressive subgroup of breast cancer with poor prognosis,high recurrence and metastasis rate,lack of effective target therapy.This study was to investigate the TNBC and base-like subgroup clinic-pathologic prognostic factors retrospectively. Methods: 124 cases of TNBC patients treated in Tumor Hospital of Jiangsu Province were enrolled in the research.Fisher precise method was used to examine the association between clinical characteristics.Kaplan-Meier method was performed to examine the association between p53/Ki-67 and disease free survival time(DFS) in TNBC and base-like subgroup.Univariate and multivariate analyses of COX model were used to distinguish the independent prognosis factors of DFS(disease free survival). Results: Base-like subgroup accounted for 48.3 % of TNBC.p53 was positive in 46.8% and the Ki-67 high index was in 55.6% of TNBC.Positive p53 was associated with histological grade and high Ki-67 with lymph node metastasis.Lymphatic metastasis,serious clinical stage,positive p53 and Ki-67 high index significantly associated with high risk of recurrence and poor DFS of TNBC and base-like subgroup. Conclusion: This study indicated that lymphatic metastasis,clinical stage,p53,Ki-67 may be prognostic factors in TNBC.
作者 曹洁 唐金海 Cao Jie;Tang Jinhai(Department of Medical Oncology,Jiangsu Cancer Hospital,Jiangsu Institute of Cancer Research,The Affiliated Cancer Hospital of Nanjing Medical University,Jiangsu Nanjing 210000,China;Department of General Surgery,the People's Hospital of Jiangsu Province Affiliated to Nanjing Medical University,Jiangsu Nanjing 210000,China.)
出处 《现代肿瘤医学》 CAS 2018年第12期1852-1856,共5页 Journal of Modern Oncology
基金 江苏省自然科学基金(编号:BK20151579)
关键词 三阴性乳腺癌 KI-67 p53 无病生存期 预后因子 triple negative breast cancer Ki-67 p53 disease free survival time prognostic factor
  • 相关文献

参考文献1

二级参考文献11

  • 1Sotiriou C,Pusztai L.Gene-expression signatures in breast cancer[J].N Engl J Med,2009,360(8):790-800.
  • 2Perou CM,Serlie T,Eisen MB,et al.Molecular portraits of human breast tumours[J].Nature,2000,406 (6797):747-752.
  • 3Desmedt C,Haibe Kains B,Wirapati P,et al.Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes[J].Clin Cancer Res,2008,14(16):5158-5165.
  • 4Hugh J,Hanson J,Cheang MC,et al.Breast cancer subtypes and response to docetaxel in node-positive breast cancer:use of an immunohistochemical definition in the BCIRG 001 Trial[J].J Clin Oncol,2009,27(8):1168-1176.
  • 5Hammond ME,Hayes DF,Dowsett M,et al.American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer[J].J Clin Oncol,2010,28(16):2784-2795.
  • 6Wolff AC,Hammond ME,Schwartz JN,et al.American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer[J].J Clin Oncol,2007,25 (1):118-145.
  • 7Hammond ME,Hayes DF,Wolff AC.Clinical notice for American Society of Clinical Oncology-College of American Pathologists guideline recommendations on ER/PgR and HER-2 testing in breast cancer[J].J Clin Oncol,2011,29 (15):e458.
  • 8Goldhirsch A,Wood WC,Coates AS,et al.Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011[J].Ann Oncol,2011.doi:10.1093/annonc/mdr304.
  • 9Giuliano AE,Hunt KK,Ballman KV,et al.Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis:a randomized clinical trial[J].JAMA,2011,305(6):569-575.
  • 10Swain SM,Jeong JH,Wolmark N.Amenorrhea from breast cancer therapy-not a matter of dose[J].N Engl J Med,2010,363(23):2268-2270.

共引文献34

同被引文献21

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部